MorphoSys
Driven by our mission: More life for people with cancer.
Driven by our mission: More life for people with cancer.
Constellation Pharmaceuticals, A MorphoSys Company
Driven by our mission: More life for people with cancer.
In July 2021, MorphoSys acquired Constellation Pharmaceuticals. This transformational acquisition bolstered MorphoSys’ position as a leader in hematology and oncology and marked the beginning of an important next chapter in the company's history.
MorphoSys’ mission is more life for people with cancer. As a global commercial-stage biopharmaceutical company, MorphoSys uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
Read more about the acquisition here.
Learn more about MorphoSys: www.MorphoSys.com
Founded: 2008
Industries: Biotechnology, Pharmaceutical
Headquarters: United States
Last Investment: $224.30MPost-IPO Equity investment at 10 December 2019
Last Investment Investors:
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | €102.70M | - | 14 Dec 2023 | |
| Post-IPO Debt | €325.00M | - | 13 Oct 2020 | |
| Post-IPO Equity | €115.00M | - | 06 Nov 2016 | |
| Post-IPO Equity | $126.00M | - | 19 Sep 2013 | |
| Seed Round | Unknown | 1 |
|
02 Jan 1992 |
No recent news or press coverage available for MorphoSys.
We care about your data, and we'd love to use cookies make your experience better.
